RankingsPricing
  1. JP-listed companies
  2. TAIKO PHARMACEUTICAL CO., LTD.

TAIKO PHARMACEUTICAL CO., LTD.JP:4574

Market cap
¥20.3B
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Mar 31,
2013		Mar 31,
2014		Mar 31,
2015		Mar 31,
2016		Mar 31,
2017		Mar 31,
2018		Mar 31,
2019		Mar 31,
2020		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023
Profit (loss) before income taxes1,1012,5542,7591,1921,4911,5531,9863,5045,374-8,887-4,869-3,563
Depreciation251259281351445454461495473941737704
Impairment losses-88-32-----2,453912,502
Loss (gain) on sale of non-current assets40-1-104-2-214-----76
Loss on retirement of non-current assets-216423542780374
Premium allowance of retirement----------226-
Compensation expenses-------63-359499-
Increase (decrease) in provision for sales returns2879-2593210214130-101579-699-
Increase (decrease) in refund liabilities----------94-22
Increase (decrease) in provision for bonuses-4568-150-201218551272-145-306-12551
Increase (decrease) in retirement benefit liability----17734543963-146-34
Increase (decrease) in Provision for surcharge----------607-
Increase (decrease) in provision for loss on subleases-----------77
Interest and dividend income-5-6-9-4-2-1-9-6-6-3-5-25
Interest expenses---3---006108
Loss (gain) on sale of investment securities---58---3-1---60--221
Loss (gain) on valuation of investment securities----50-----7628
Loss (gain) on liquidation of investment securities----------6-
Foreign exchange losses (gains)-52-57-14013170-810-2-1-
Decrease (increase) in trade receivables-185483350-335364-1,584-274-777-3,5243,8992,315-175
Decrease (increase) in inventories-38-292-462423372-139-16-485-4,3803,2221,257581
Increase (decrease) in trade payables4942-180-110771491014951,944-2,661-8278
Increase (decrease) in accrued expenses-----------41973
Increase (decrease) in accounts payable - other38440-350-226-3125970270348-271-676157
Increase/decrease in consumption taxes payable/consumption taxes refund receivable--44-356501-21647170-4453275131
Other, net-561842102-16246129350121134-
Subtotal1,1003,7121,7581,0253,0555062,3024,271-108-567-884282
Interest and dividends received5577211110128925
Interest paid----3----0--6-10-8
Premium allowance of retirement paid-----------226-
Compensation expenses paid-----------859-
Surcharge paid------------607
Income taxes paid-13-127-1,075-652-359-567-566-724-1,419-1,030-23-
Net cash provided by (used in) operating activities1,0933,5896903782,698-601,7483,493-1,516-1,595-1,994-307
Payments into time deposits-212-594-816-279-196--77-263-62-8-234-22
Proceeds from withdrawal of time deposits389340535959196-45327913217106
Purchase of property, plant and equipment-212-304-2,881-3,718-112-129-303-157-2,144-1,476-64-97
Proceeds from sale of property, plant and equipment54-4391-05041--2170
Purchase of intangible assets---7-38-11-10-202-63-80-124-20-17
Proceeds from sale of investment securities-----31--80-621
Proceeds from redemption of investment securities----------300400
Purchase of shares of subsidiaries----------107-9-
Other, net-66-71-0-----5
Net cash provided by (used in) investing activities14-621-2,755-2,636-72-114-747-448-2,759-1,6221901,166
Proceeds from long-term borrowings---------5,000-500
Repayments of long-term borrowings----------316-923-1,053
Repayments of lease liabilities-18-18-15-14-15-16-18-28-26-43-44-33
Proceeds from issuance of shares resulting from exercise of share acquisition rights--------222101-2,119
Proceeds from issuance of share acquisition rights-231126-31-----13
Purchase of treasury shares-286--642-0---0-540----
Dividends paid-194-191-325-320-196-283-499-499-845-782--1
Other, net-----------29-4
Net cash provided by (used in) financing activities-45220-825-1361,249-74-338-581-6493,959-9971,539
Effect of exchange rate change on cash and cash equivalents39100106-48-68-8-18-10-21827649
Net increase (decrease) in cash and cash equivalents6943,089-2,784-2,4423,806-2556452,453-4,947823-2,7242,447